Study on Talimogene Laherparepvec (T-VEC) and Pembrolizumab for Treating Advanced Sarcoma

Inclusion Criteria

• Must be 18 years or older.
• Willing to provide written consent and follow the study protocol.
• Have a confirmed diagnosis of sarcoma that is either metastatic (spread to other parts of the body) or locally advanced and cannot be surgically removed.
• For specific types of sarcoma, such as undifferentiated pleomorphic sarcoma, myxofibrosarcoma, epithelioid sarcoma, or cutaneous angiosarcoma, patients must have these specific subtypes.
• Must have at least one tumor that can be injected, measuring at least 10 mm in diameter. Bone lesions are not eligible unless they have a soft tissue component that can be injected.
• Must have had at least one prior treatment for sarcoma, unless there is no standard treatment available for their specific type of sarcoma.
• Must be in good overall health with a performance status score of 0 or 1.
• Must have adequate organ function as determined by specific blood tests.
• Women of childbearing potential must have a negative pregnancy test before starting treatment.

Exclusion Criteria

• Have uncontrolled illness, such as an active infection or heart failure, within the last 6 months.
• Have active cancer in the brain or spinal cord, unless previously treated and stable.
• Have significant immune system suppression or are taking high doses of steroids.
• Have a history of autoimmune diseases that required treatment in the last 2 years.
• Have active herpes infections or require regular anti-herpes medication.
• Have active hepatitis B or C, or tuberculosis.
• Are pregnant, breastfeeding, or planning to become pregnant or father a child during the study.
• Are not willing to use effective birth control during the study and for a few months after.
• Have a history of severe allergic reactions to the study drugs.
• Have had recent cancer treatments or surgery and have not fully recovered.
• Are currently participating in another clinical trial or have recently participated in one.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Have another active cancer.